6xfp
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Crystal Structure of BRAF kinase domain bound to Belvarafenib== | ==Crystal Structure of BRAF kinase domain bound to Belvarafenib== | ||
| - | <StructureSection load='6xfp' size='340' side='right'caption='[[6xfp]]' scene=''> | + | <StructureSection load='6xfp' size='340' side='right'caption='[[6xfp]], [[Resolution|resolution]] 2.00Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XFP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XFP FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6xfp]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XFP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XFP FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xfp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xfp OCA], [https://pdbe.org/6xfp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xfp RCSB], [https://www.ebi.ac.uk/pdbsum/6xfp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xfp ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=V1Y:4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide'>V1Y</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">BRAF ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xfp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xfp OCA], [https://pdbe.org/6xfp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xfp RCSB], [https://www.ebi.ac.uk/pdbsum/6xfp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xfp ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the treatment of BRAF(V600)-mutant melanoma, they are ineffective in non-BRAF(V600) mutant cells(1-3). Belvarafenib is a potent and selective RAF dimer (type II) inhibitor that exhibits clinical activity in patients with BRAF(V600E)- and NRAS-mutant melanomas. Here we report the first-in-human phase I study investigating the maximum tolerated dose, and assessing the safety and preliminary efficacy of belvarafenib in BRAF(V600E)- and RAS-mutated advanced solid tumours (NCT02405065, NCT03118817). By generating belvarafenib-resistant NRAS-mutant melanoma cells and analysing circulating tumour DNA from patients treated with belvarafenib, we identified new recurrent mutations in ARAF within the kinase domain. ARAF mutants conferred resistance to belvarafenib in both a dimer- and a kinase activity-dependent manner. Belvarafenib induced ARAF mutant dimers, and dimers containing mutant ARAF were active in the presence of inhibitor. ARAF mutations may serve as a general resistance mechanism for RAF dimer inhibitors as the mutants exhibit reduced sensitivity to a panel of type II RAF inhibitors. The combination of RAF plus MEK inhibition may be used to delay ARAF-driven resistance and suggests a rational combination for clinical use. Together, our findings reveal specific and compensatory functions for the ARAF isoform and implicate ARAF mutations as a driver of resistance to RAF dimer inhibitors. | ||
| + | |||
| + | ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.,Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S Nature. 2021 May 5. pii: 10.1038/s41586-021-03515-1. doi:, 10.1038/s41586-021-03515-1. PMID:33953400<ref>PMID:33953400</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6xfp" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Sudhamsu J]] | + | [[Category: Sudhamsu, J]] |
| - | [[Category: Yin J]] | + | [[Category: Yin, J]] |
| + | [[Category: Braf belvarafenib]] | ||
| + | [[Category: Signaling protein]] | ||
Revision as of 12:25, 9 June 2021
Crystal Structure of BRAF kinase domain bound to Belvarafenib
| |||||||||||
